Arbutus Biopharma Corporation
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease. We are currently developing imdusiran (AB-729), our proprietary, GalNAc-conjugated, subcutaneously-delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, our proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B virus.
Find Arbutus Biopharma Corporation Execs' Valid Emails
Up to 90% verified emails and mobile numbers, refreshed weekly.
Company Details
5M-10M
Biotechnology Research
11-50 employees
Public Company
Warminster, Pennsylvania
United States
Frequently Asked Questions about
What is Arbutus Biopharma Corporation's industry?
Arbutus Biopharma Corporation operates in the Biotechnology Research industry and is headquartered in United States.
How many employees does Arbutus Biopharma Corporation have?
Arbutus Biopharma Corporation has approximately 11-50 employees employees.
Where is Arbutus Biopharma Corporation's based?
Arbutus Biopharma Corporation is based in Warminster, Pennsylvania, United States.
Is Arbutus Biopharma Corporation publicly listed?
Yes. Arbutus Biopharma Corporation is a publicly traded company.
How can I contact Arbutus Biopharma Corporation's investor relations team?
You can reach Arbutus Biopharma Corporation’s investor relations department through the contact section on their official website or directly via the investor relations email listed in their latest SEC filings.
Find verified emails and phone numbers for professionals like those at
Up to 90% verified emails and mobile numbers, backed by weekly job-change alerts.
Find verified emails at this company
An email pattern tells you the format. It does not tell you who works there now or whether an address still delivers. Scalelist returns verified contacts, checked at the point you build the list.